Merck & Co.
AWARDS
NEWS
During the 2016 U.S. presidential election, the push for lower drug prices became one of the hot-button topics. Now there appears to be some efforts by advocacy groups and government entities to tackle the subject in several different ways.
Sometimes it feels like biotech’s successes and failures come in waves—even when it involves entirely unrelated clinical programs. This past month has had many in industry feeling like they’re underwater.
Industry watchers and investors have shown some concern that Merck is abandoning other potentially lucrative areas of research to focus on exploiting every last bit of Keytruda’s potential
Roche announced it had temporarily halted recruiting patients to its Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths. The patients were receiving Tecentriq (atezolizumab) in combination with Exelixis’ MEK inhibitor Cotellic (cobimetinib).
Merck & Co. is chalking up another clinical win for its potent checkpoint inhibitor Keytruda. This morning the company announced the anti-PD-1 therapy hit its endpoints as a first-line monotherapy in lung cancer following an interim review of data.
Genentech is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.
JOBS
IN THE PRESS